Humacyte Inc. (HUMA) Share Price Today, Stock Analysis, Annual Report | Value Research Humacyte Inc. (HUMA) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.
  • Price Change
  • Market Capitalisation market-capitalisation-info $338 Mln

  • 12 Month Earnings monthly-earning $-29 Mln
  • Price to Earnings price-to-earning --

Humacyte Inc. (HUMA) Share Price

$2.93

As on 29-Sep-2023 16:00 EDT

up-down-arrow $0.010.34%

  • Prev Close info

    $2.92

  • Day's Openinfo

    $2.92

  • Today's Highinfo

    $2.95

  • Today's Lowinfo

    $2.86

  • Today's Volumeinfo

    274,627

Please wait...

Humacyte Inc. (HUMA) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Humacyte (HUMA)
38.86 -26.38 -3.30 -17.46 -- -- --
S&P BSE Sensex
8.20 1.28 2.99 16.31 20.12 12.69 12.81
S&P Small-Cap 600#
-0.54 -5.85 -5.24 7.40 10.50 1.63 6.62
As on 29-Sep-2023  |  #As on 30-Sep-2023
2022
Humacyte (HUMA)
-70.90
S&P Small-Cap 600
-17.42
S&P BSE Sensex
4.44

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Humacyte Inc. (HUMA) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Humacyte Inc. (HUMA)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Founder, Pres, CEO & Director

        Dr. Laura E. Niklason M.D., Ph.D.

        CFO, Chief Corp. Devel. Officer & Treasurer

        Mr. Dale A. Sander

        Headquarters

        Durham, NC

        FAQs for Humacyte Inc. (HUMA)

        The total asset value of Humacyte Inc. (HUMA) stood at $ 207 Mln as on 31-Mar-23

        The share price of Humacyte Inc. (HUMA) is $2.930000 (NASDAQ) as of 29-Sep-2023 16:00 EDT. Humacyte Inc. (HUMA) has given a return of -17.46% in the last 1 years.

        Humacyte Inc. (HUMA) has a market capitalisation of $ 338 Mln as on 11-Aug-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Humacyte Inc. (HUMA) is 2.40 times as on 11-Aug-2023, a -0.06% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Humacyte Inc. (HUMA) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Humacyte Inc. (HUMA) and enter the required number of quantities and click on buy to purchase the shares of Humacyte Inc. (HUMA).

        Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

        The CEO & director of Dr. Laura E. Niklason M.D., Ph.D.. is Humacyte Inc. (HUMA), and CFO & Sr. VP is Mr. Dale A. Sander.

        The promoters of Humacyte Inc. (HUMA) have pledged 0% of the total equity as on Mar-23.

        Humacyte Inc. (HUMA) Ratios
        Return on equity(%)
        18.52
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0.2
        Dividend yield(%)
        0

        No, TTM profit after tax of Humacyte Inc. (HUMA) was $-29 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $338.14 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-29.10 Mln
        • Cash date-information $131.68 Mln
        • Total Debt info $47.52 Mln
        • Insider's Holding 39.70%
        • Liquidity liquidity High
        • 52 Week range week-range $1.96 - 5.60
        • Shares outstanding share-outstanding 103,408,000

        About The Company

        • IPO Date 26-Aug-2021
        • Founder, Pres, CEO & Director Dr. Laura E. Niklason M.D., Ph.D.
        • CFO, Chief Corp. Devel. Officer & Treasurer Mr. Dale A. Sander
        • Listing key-listing NASDAQ: HUMA
        • Country United States
        • Headquarters headquarters Durham, NC
        • Website website https://www.humacyte.com
        • Business

          Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company...  using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon